IL-17A in diabetic kidney disease: protection or damage

作者：Tan, Hai-Bo^*; Zheng, Yan-Qiu; Zhuang, Yu-Pei

来源：International Immunopharmacology, 2022, 108: 108707.

DOI：10.1016/j.intimp.2022.108707

• Diabetic kidney disease
• IL-17A
• Inflammation
• Fibrosis

The effect of IL-17A in diabetic kidney disease (DKD) has received increasing attention. Interleukin (IL)-17A promotes renal inflammation and the progression of DKD, and IL-17A deficiency improves experimental DKD. However, recent studies have found that the effect of IL-17A on DKD is more complicated than the negative impact. IL-17A alleviates renal inflammation and fibrosis via regulating autophagy or the macrophage phenotype. Moreover, paradoxical expression of IL-17A has been reported in human DKD. This review focuses on how IL-17A affects the progression of DKD and the resulting opportunities and challenges.

• 单位
  广州中医药大学; 1; 广东药学院